Negative / Null Result ReportOpen accessMedicine· cited by 9

Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data

Gustavo Jimenez‐Maggiora; Arndt‐Peter Schulz; Michael Donohue; Hongbin Qiu; S N Jaiswal; Olusegun Adegoke; Rodrigo A. Gallardo; O Baryshnikava · 2024 · The Journal of Prevention of Alzheimer s Disease

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

BACKGROUND: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies were conducted between 2014 and 2023, with enrollment completed in 2017 and final study results reported in 2023. The study screening process involved the collection of initial clinical, cognitive, neuroimaging, and genetic measures to determine eligibility. Once randomized, enrolled participants were assessed every four weeks over a 4.5-year follow-up period during which longitudinal clinical, cognitive, and neuroimaging measures wer

Abstract by Gustavo Jimenez‐Maggiora; Arndt‐Peter Schulz; Michael Donohue; Hongbin Qiu; S N Jaiswal; Olusegun Adegoke; Rodrigo A. Gallardo; O Baryshnikava, The Journal of Prevention of Alzheimer s Disease (2024) — licensed CC BY 4.0.

Read the full paper (open access)